Drug Trial Fails For Human Genome And GlaxoSmithKline

Human Genome Sciences Inc. (Nasdaq: HGSI) and GlaxoSmithKline (NYSE: GSK) announced that their lupus treatment Benlysta failed secondary goals in a late stage clinical trial. Shares of Human Genome tumbled $2.98 to $28.51 while GlaxoSmithKline stock edged up 13 cents to $39.51.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.